MethylGene appoints Peggy Mulligan as director

Former chief financial officer of Valeant Pharmaceuticals Peggy Mulligan has joined the board of directors at Canada-based MethylGene.

Charles Grubsztajn, president and CEO of the small molecule drug development company, highlighted Mulligan's experience in finances and auditing as reasons for her appointment.

“We look forward to her guidance as we plan for the future,” he said.

Mulligan had previously been chief financial officer and executive VP at Biovail before its merger with Valeant in September 2010 in which she played a key role, co-leading the merger and subsequent integration between the two companies.

She resigned from Valeant in December 2010, just three months after the merger, to pursue other interests.

Prior to her time at Biovail/Valeant, Mulligan served as executive VP and chief financial officer and treasurer of Linamar Corporation from 2005 to 2007.

Previously, she spent eleven years in various roles at the Bank of Nova Scotia, most recently as executive VP, systems and operations.

In 2003 and 2004 Mulligan was also named one of Canada's Top 100 Most Powerful Women by the Women's Executive Network.